| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg | |||
| Other Sizes |
| Targets |
The primary target of ABT-100 is farnesyltransferase (FTase), an enzyme that catalyzes the farnesylation of proteins, including the oncogene Ras. By inhibiting FTase, ABT-100 prevents the farnesylation of Ras, which is required for its membrane localization and activity. This inhibits the proliferation of cells carrying oncogenic H-Ras. The compound's selectivity for FTase over geranylgeranyltransferase is confirmed by its inability to inhibit Rap1A geranylgeranylation.
|
|---|---|
| ln Vitro |
In human pancreatic system, ABT-100 (0.1-100 nM; 7 days; EJ-1, DLD-1, MDA-MB-231, HCT-116, MiaPaCa-2, PC-3, and DU-145 cells) therapy exhibits dose-cycle growth inhibition. At doses similar to ABT-100 cytokine attachment staining proliferation, cytokine colonies can also form [1].
In vitro, ABT-100 is a potent inhibitor of farnesyltransferase. It inhibits cell proliferation with IC₅₀s of 2.2 nM. It inhibits Ras farnesylation but not Rap1A geranylgeranylation in HepG2 and Huh7 cells at 20 µM. The compound's activity is characterized in cell-based assays measuring the inhibition of cell proliferation and the reduction of farnesylated Ras levels. |
| ln Vivo |
The model's EJ-1 tumors shrank as a result of ABT-100 (6.25–12.5 mg/kg/day; subcutaneous injection; daily; for 21 days; CB-17 scid model) treatment [1].
In vivo, ABT-100 is an orally active farnesyltransferase inhibitor. Its efficacy has been evaluated in animal models of cancer, where it has shown the ability to inhibit tumor growth. The compound's oral bioavailability and pharmacokinetic profile make it suitable for in vivo administration. |
| Enzyme Assay |
In vitro enzyme assays for ABT-100 measure its inhibition of farnesyltransferase activity. The enzyme is incubated with a substrate, such as farnesyl pyrophosphate and a Ras peptide, and the transfer of the farnesyl group is measured. The compound's IC₅₀ is determined from dose-response curves. Selectivity over geranylgeranyltransferase is assessed by testing against this related enzyme.
|
| Cell Assay |
Cell Proliferation Analysis[1]
Cell Types: EJ-1, DLD-1, MDA -MB-231, HCT-116, MiaPaCa-2, PC-3 and DU-145 Cell Tested Concentrations: 0.1-100 nM Incubation Duration: 7 days Experimental Results: Demonstrated dose-dependent growth inhibition on human cancer cell lines. In vitro cell-based assays for ABT-100 evaluate its effects on cell proliferation and Ras signaling. Cells are treated with the compound, and cell viability is measured using MTT or CellTiter-Glo assays. The farnesylation status of Ras is assessed by Western blot using antibodies that recognize farnesylated Ras. The compound's effects on downstream signaling pathways, such as the MAPK pathway, can also be evaluated. |
| Animal Protocol |
Animal/Disease Models: CB-17 scid male mice with EJ-1 cells [1]
Doses: 6.25 mg/kg/day, 12.5 mg/kg/day Route of Administration: subcutaneous injection; daily; continued for 21 days Experimental Results: CB EJ-1 tumor regression in -17 scid male mice. In vivo animal studies for ABT-100 are conducted in xenograft mouse models. Tumor-bearing mice are treated with the compound orally, and tumor growth inhibition is monitored. Pharmacodynamic studies measure the inhibition of Ras farnesylation in tumor tissues. Pharmacokinetic studies determine the compound's half-life and bioavailability. |
| ADME/Pharmacokinetics |
The pharmacokinetic properties of ABT-100 are consistent with an orally active compound. Its molecular weight is 504.46 g/mol. The compound has a relative density of 1.29 g/cm³. For research use, it is typically stored as a powder at -20°C. Further details on its half-life, Cmax, and bioavailability are available from the primary research literature.
|
| Toxicity/Toxicokinetics |
The toxicity profile of ABT-100 has been evaluated in preclinical studies. As a farnesyltransferase inhibitor, its potential side effects may include gastrointestinal and hematological toxicities. The compound is for research use only and is not intended for human therapeutic applications.
|
| References | |
| Additional Infomation |
Additional information: ABT-100 is a potent and orally active farnesyltransferase inhibitor. It inhibits cell proliferation with IC₅₀s of 2.2 nM. The compound is a chemical probe for studying the role of farnesylation in cancer and other diseases. This product is for research use only and is not approved for clinical or therapeutic applications.
|
| Molecular Formula |
C27H19F3N4O3
|
|---|---|
| Molecular Weight |
504.46
|
| Exact Mass |
504.141
|
| Elemental Analysis |
C, 64.28; H, 3.80; F, 11.30; N, 11.11; O, 9.51
|
| CAS # |
450839-40-4
|
| Related CAS # |
852926-14-8 (HCl) 450839-40-4
|
| PubChem CID |
6451154
|
| Appearance |
white solid powder
|
| Density |
1.29g/cm3
|
| Boiling Point |
722ºC at 760 mmHg
|
| Flash Point |
390.5ºC
|
| Index of Refraction |
1.589
|
| LogP |
5.043
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
37
|
| Complexity |
854
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
FC(OC1C([H])=C([H])C(=C([H])C=1[H])C1C([H])=C(C#N)C([H])=C([H])C=1OC([H])([H])[C@](C1C([H])=C([H])C(C#N)=C([H])C=1[H])(C1=C([H])N=C([H])N1C([H])([H])[H])O[H])(F)F
|
| InChi Key |
HEUVRFNVTLGKMZ-SANMLTNESA-N
|
| InChi Code |
InChI=1S/C27H19F3N4O3/c1-34-17-33-15-25(34)26(35,21-7-2-18(13-31)3-8-21)16-36-24-11-4-19(14-32)12-23(24)20-5-9-22(10-6-20)37-27(28,29)30/h2-12,15,17,35H,16H2,1H3/t26-/m0/s1
|
| Chemical Name |
(S)-6-(2-(4-cyanophenyl)-2-hydroxy-2-(1-methyl-1H-imidazol-5-yl)ethoxy)-4'-(trifluoromethoxy)-[1,1'-biphenyl]-3-carbonitrile
|
| Synonyms |
A367074 ABT-100A-367074ABT100A 367074 ABT 100
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~99.12 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9823 mL | 9.9116 mL | 19.8232 mL | |
| 5 mM | 0.3965 mL | 1.9823 mL | 3.9646 mL | |
| 10 mM | 0.1982 mL | 0.9912 mL | 1.9823 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
